PULMONARY ARTERIAL HYPERTENSION

This early-stage trial tests whether transplanting gut bacteria from healthy donors, along with antibiotics and fiber, is safe and feasible for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. About 24 adults with PAH will be ran…

This trial tests whether an experimental drug called CS1, taken as a daily pill, can improve blood vessel function in people with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes the heart work harder. Participants will receive CS1 o…

This study tests the safety of a new medicine called sotatercept for adults in India with pulmonary arterial hypertension (PAH), a condition where blood vessels in the lungs become narrow, making breathing hard. About 30 people will receive sotatercept along with their usual trea…

This trial investigates whether semaglutide, a GLP-1 agonist, can shift how the heart produces energy in people with pulmonary arterial hypertension (PAH). The heart in PAH often relies on inefficient fuel sources, and the drug may help it switch to a more efficient form. Researc…

This study tests whether people with pulmonary arterial hypertension (PAH) who are doing well on the drug sotatercept can safely stop their background prostacyclin therapy. Prostacyclin drugs can cause side effects and are hard to manage. The trial compares patients who slowly st…

This phase 2 trial tests a dietary supplement called 2-HOBA in 12 adults with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs strains the heart. Participants take the supplement three times daily for 12 weeks. The study checks if 2-HOBA i…

This study tests the safety and tolerability of sotatercept in Japanese children aged 1 to 18 with pulmonary arterial hypertension (PAH), a condition where blood vessels in the lungs narrow, making the heart work harder. Participants receive sotatercept injections every three wee…

This study is checking the long-term safety of a daily pill called IKT-001 for people with pulmonary arterial hypertension (PAH), a serious lung condition. About 484 adults who have already completed an earlier IKT-001 study will take the drug for an extended period. Researchers …

This Phase 3 study tests VI-0106, an extended-release form of tacrolimus, in 300 people with pulmonary arterial hypertension (PAH) who still have trouble with daily activities despite taking standard PAH medications. Participants will receive either the drug or a placebo for 24 w…

This Phase 2 trial tests an oral drug called NS-863 in 135 adults with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes it hard to breathe. Participants will receive either a low dose, high dose, or placebo for 24 weeks. The main goa…

This study looks at how tiny particles called extracellular vesicles travel through the bloodstream in people with systemic sclerosis, an autoimmune disease that affects blood vessels and organs. Researchers will take blood samples from different points in the circulation to see …

This study follows 60 adults with pulmonary hypertension (high blood pressure in the lungs) for 2 years. Researchers will measure breathing problems during sleep and heart rate changes to see how they relate to the disease. No new treatment is given; participants continue their u…

This study looks at how changes in the cells lining blood vessels relate to lung resistance in people with pulmonary artery hypertension (PAH). Researchers will measure certain blood markers and lung pressure in 6 adults with PAH. The goal is to better understand the disease, not…

This observational study will review medical records of 15 adults with pulmonary arterial hypertension (PAH) who switched from one medication (a PDE5 inhibitor) to riociguat while already on triple therapy. The goal is to see if this switch improves exercise ability, symptoms, an…